Bank of New Hampshire Trims Stake in Stryker Co. (NYSE:SYK)

Bank of New Hampshire reduced its position in shares of Stryker Co. (NYSE:SYK) by 1.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,178 shares of the medical technology company’s stock after selling 194 shares during the quarter. Stryker comprises about 1.6% of Bank of New Hampshire’s portfolio, making the stock its 14th biggest position. Bank of New Hampshire’s holdings in Stryker were worth $6,022,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Miracle Mile Advisors LLC increased its holdings in Stryker by 13.0% during the 1st quarter. Miracle Mile Advisors LLC now owns 7,569 shares of the medical technology company’s stock worth $2,818,000 after purchasing an additional 870 shares during the period. Wedmont Private Capital increased its holdings in Stryker by 5.6% during the 1st quarter. Wedmont Private Capital now owns 3,876 shares of the medical technology company’s stock worth $1,358,000 after purchasing an additional 207 shares during the period. Orrstown Financial Services Inc. increased its holdings in Stryker by 27.8% during the 1st quarter. Orrstown Financial Services Inc. now owns 809 shares of the medical technology company’s stock worth $301,000 after purchasing an additional 176 shares during the period. Sivia Capital Partners LLC increased its holdings in Stryker by 4.0% during the 1st quarter. Sivia Capital Partners LLC now owns 1,070 shares of the medical technology company’s stock worth $398,000 after purchasing an additional 41 shares during the period. Finally, Piscataqua Savings Bank increased its holdings in Stryker by 1.4% during the 1st quarter. Piscataqua Savings Bank now owns 3,726 shares of the medical technology company’s stock worth $1,387,000 after purchasing an additional 50 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares of the company’s stock, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.90% of the stock is currently owned by insiders.

Stryker Stock Up 0.3%

Stryker stock opened at $384.15 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market capitalization of $146.63 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 2.93 and a beta of 0.91. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The business has a fifty day moving average price of $370.10 and a 200-day moving average price of $375.96.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. During the same quarter in the previous year, the firm posted $2.50 EPS. The firm’s revenue was up 11.9% compared to the same quarter last year. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio is currently 45.41%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Friday, March 21st. The Goldman Sachs Group set a $422.00 price target on Stryker in a report on Tuesday, March 4th. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Monday, May 5th. Finally, Barclays lifted their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.